文献速递白血病淋巴瘤

奥加伊妥珠单抗用于55岁以上费城染色体阴性B前体急性淋巴细胞白血病患者的诱导治疗

Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
PubMed 文献 · J Clin Oncol · 2023-10-26

INITIAL-1是一项开放标签、多中心、II期试验,纳入45例55岁以上新诊断CD22阳性BCR::ABL阴性B前体急性淋巴细胞白血病患者,接受最多3周期奥加伊妥珠单抗/地塞米松诱导及最多6周期年龄适配GMALL巩固维持治疗。43例可评估患者全部达完全缓解,1年无事件生存率88%(95%CI 79-98),3年55%(95%CI 40-71);1年总生存率91%(95%CI 82-99),3年73%(95%CI 59-87)。

要点

  • 43例可评估患者全部达完全缓解(CR/CRi)。
  • 第二次和第三次诱导后分别有23例(53%)和30例(71%)无可检测的分子学微小残留病(最低阈值10e-4)。
  • 诱导期间常见≥3级不良事件为白细胞减少、中性粒细胞减少、血小板减少、贫血和肝酶升高。

核心结论

  • 以奥加伊妥珠单抗为基础的诱导后接年龄适配化疗耐受性良好,并获得高缓解率和高总生存率。
  • 这些数据为将奥加伊妥珠单抗整合入老年B-ALL患者一线方案提供了依据。

研究设计与样本

  • 开放标签、多中心、II期INITIAL-1试验纳入45例55岁以上新诊断、CD22阳性、BCR::ABL阴性B前体急性淋巴细胞白血病(B-ALL)患者。
  • 患者接受最多3周期奥加伊妥珠单抗/地塞米松诱导及最多6周期年龄适配GMALL巩固和维持治疗。
  • 43例可评估患者中常见/前B型38例、原B型5例,中位年龄64岁(范围56-80),至少接受2周期奥加伊妥珠单抗诱导治疗。

主要发现

  • 所有患者均达完全缓解(CR/CRi)。
  • 第二次和第三次诱导后分别有23例(53%)和30例(71%)无可检测的分子学微小残留病(最低阈值10e-4)。
  • 中位随访2.7年后,1年(主要终点)和3年无事件生存率分别为88%(95%CI 79-98)和55%(95%CI 40-71)。
  • 1年和3年总生存率分别为91%(95%CI 82-99)和73%(95%CI 59-87)。
  • 诱导开始后6个月内无患者死亡;诱导期间常见≥3级不良事件为白细胞减少、中性粒细胞减少、血小板减少、贫血和肝酶升高;1例患者在第二次诱导后发生非致死性静脉闭塞性疾病。

关键数值与推荐

  • 主要终点为1年无事件生存率88%(95%CI 79-98)。
  • 3年无事件生存率55%(95%CI 40-71),1年总生存率91%(95%CI 82-99),3年总生存率73%(95%CI 59-87)。
  • 分子学微小残留病阴性(最低阈值10e-4):第二次诱导后23例(53%),第三次诱导后30例(71%)。

临床怎么用

  • 作者认为这些数据为将奥加伊妥珠单抗整合入老年B-ALL患者一线方案提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite recent advances in adapting the intensity of treatment for older patients with ALL, current protocols are associated with high rates of early deaths, treatment-related toxicity, and dismal prognosis. We evaluated inotuzumab ozogamicin and dexamethasone (Dex) as induction therapy in older patients with ALL within the German Multicenter Study Group for Adult ALL (GMALL). PATIENTS AND METHODS: The open-label, multicenter, phase II, INITIAL-1 trial enrolled 45 patients older than 55 years with newly diagnosed, CD22-positive, BCR::ABL-negative B-precursor ALL (B-ALL). Patients received up to three cycles of inotuzumab ozogamicin/Dex and up to six cycles of age-adapted GMALL consolidation and maintenance therapy. RESULTS: Forty-three evaluable patients with common/pre-B (n = 38) and pro-B ALL (n = 5), with a median age of 64 years (range, 56-80), received at least two cycles of inotuzumab ozogamicin induction therapy. All patients achieved complete remission (CR/CR with incomplete hematologic recovery). Twenty-three (53%) and 30 (71%) patients had no evidence of molecularly assessed measurable residual disease (minimum 10e-4 threshold) after the second and third inductions, respectively. After a median follow-up of 2.7 years, event-free survival at one (primary end point) and 3 years was 88% (95% CI, 79 to 98) and 55% (95% CI, 40 to 71), while overall survival (OS) was 91% (95% CI, 82 to 99) and 73% (95% CI, 59 to 87), respectively. None of the patients died during 6 months after the start of induction. Most common adverse events having common toxicity criteria grade ≥3 during induction were leukocytopenia, neutropenia, thrombocytopenia, anemia, and elevated liver enzymes. One patient developed nonfatal veno-occlusive disease after induction II. CONCLUSION: Inotuzumab ozogamicin-based induction followed by age-adapted chemotherapy was well tolerated and resulted in high rates of remission and OS. These data provide a rationale for integrating inotuzumab ozogamicin into first-line regimens for older patients with B-ALL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stelljes M, Raffel S, Alakel N, et al. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL. J Clin Oncol. 2023. PMID: 37883727. doi:10.1200/JCO.23.00546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。